<DOC>
	<DOCNO>NCT01681212</DOCNO>
	<brief_summary>The purpose study determine survival rate 1 year treatment ipilimumab plus dacarbazine patient previously untreated Stage III ( unresectable ) Stage IV melanoma .</brief_summary>
	<brief_title>Phase 2 Study Ipilimumab Plus Dacarbazine Japanese Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key inclusion criterion : Japanese patient histologic diagnosis malignant melanoma Previously untreated Stage III N3 ( unresectable ) Stage IV melanoma Prior adjuvant melanoma therapy permit Eastern Cooperative Oncology Group performance status 0 1 Life expectancy least 16 week study Adequate bone marrow renal hepatic function , specifically : white blood cell count ≥2500/uL , absolute neutrophil count ≥1000/uL , platelet count ≥75,000/uL , hemoglobin level ≥9.0 g/dL , creatinine level ≤2.5*upper limit normal ( ULN ) , aspartate transaminase/alanine transaminase level &lt; 2.5*ULN patient without liver metastasis &lt; 5*ULN patient liver metastasis , total bilirubin level &lt; 1.5*ULN ( Gilbert 's Syndrome , low 3.0 mg/dL ) Key exclusion criterion : Evidence brain metastasis brain image Active brain metastasis symptoms require corticosteroid treatment ; patient malignancy diseasefree few 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix Primary ocular mucosal melanoma History current active autoimmune disease History concurrent disease gastrointestinal perforation HIV infection ; active Hepatitis B C human Tlymphotropic virus type1 infection , base test performed screening period study Prior concomitant therapy anticancer agent melanoma , investigational anticancer therapy Prior adjuvant therapy &lt; 4 week prior start study drug administration Concomitant therapy immunosuppressive agent , surgery , radiotherapy Prior treatment CTLA4 inhibitors/agonists experimental immunotherapy drug Treatment investigational product within 4 week prior initial treatment study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>